The blunted reduction of LDL levels compare to the reported trials might be explained by the concomitant therapy with steroids and other immunosuppressive medications, which themselves have been shown to lead to dyslipidaemia after transplantation [13] and may counteract the PCSK9 inhibition. The gene discussed is PCSK9; the disease is inherited lipid metabolism disorder.